Biosimilars | Access & Reimbursement | US/EU | 2023
Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential reimbursement. Although biosimilars such as Pfizer’s Inflectra and Retacrit are available both in Europe and the United States, their success may vary because of regional differences in the drivers of and barriers to biosimilar uptake. As such, it is necessary for biosimilars developers and manufacturers of branded biologics to understand which factors influence payer decisions regarding biosimilars.
Questions answered:
- What are payers’ perspectives on the drivers of and barriers to biosimilars uptake?
- What factors influence which biosimilars are preferred on formularies in the United States?
- How do payers choose among multiple biosimilars of the same brand in the EU?
- What strategies do payers use to manage biosimilars?
- What expectations do payers have for biosimilars discounts?
- How would the availability of biosimilars influence the pricing of emerging agents?
- Will payer strategies for biosimilars differ between therapeutic specialties?
- Has COVID-19 affected the use or coverage of biosimilars?
Key markets covered:
- France
- Germany
- Italy
- Spain
- United Kingdom
- United States
Key companies mentioned:
- Amgen
- Biocon
- Biogen
- Boehringer Ingelheim
- Celltrion
- Eli Lilly
- Janssen
- Johnson & Johnson
- Merck & Co.
- Mundipharma
- Viatris (Mylan)
- Novartis
- Pfizer
- Roche
- Samsung Bioepis
- Sandoz
- Sanofi
- Teva
Key drugs mentioned:
- Admelog / Insulin Lispro Sanofi
- Aranesp
- Avastin
- Avsola
- Basaglar / Abasaglar
- Benepali
- Binocrit
- Enbrel
- Flixabi
- Fulphila
- Herceptin
- Herzuma
- Hulio
- Humalog
- Humira
- Inflectra
- Kanjinti
- Lantus
- Levemir
- Mvasi
- Neulasta
- Neupogen
- Nivestim / Nivestym
- NovoLog / NovoRapid
- Nyvepria
- Ogivri
- Ontruzant
- Procrit / Epogen
- Remicade
- Remsima
- Retacrit
- Riabni
- Rituxan / MabThera
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Zarzio / Zarxio
- Ziextenzo
- Zirabev
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…
